China Company Research--Beijing Tiantan Biological Products Co., Ltd.

China Company Research--Beijing Tiantan Biological Products Co., Ltd.

Beijing Tiantan Biological Products Co., Ltd. (abbreviation: Tiantan Biological) is a listed high-tech company. Tiantan Biological is among one of the largest biological products research and production base in China. Its main business is all types of vaccines, blood products, diagnostic supplies biological products’ research& development, production and sales. Leading products, including recombinant yeast hepatitis B vaccine, polio vaccine, leprosy vaccine2, leprosy vaccine3, encephalitis inactivated vaccine vero cellB, human serum albumin, IVIG, , and other kinds of diagnostic reagents. Main products occupy more than 50 per cent of the domestic market. Through independent research and development, cooperation, and the introduction of various forms to develop new products, such as interferon ß, Hib, varicella vaccine will be into the market.

In 2007, the company’s operating income, operating profit increased 28.2%, 44.5%. Company's operating costs and administration costs decreased 0.7 and 4.7 percent year-on-year, the financial costs ratio increased 1.6 percent year-on-year, the costs during the period decreased 3.7 percent year-on-year. The receivable turnover ratio and inventory turnover rate remained steadily. Asset liability ratio dropped by 1.6 percentage points, flow rate have risen.


Domestic vaccine industry has been blooming; the current market scale is around 30 billion yuan, the Government intends to inject 2.8 billion yuan to expand the immunization system, which will greatly promote the development of the vaccine market. The Ministry of Health has issued a document "the planning of expansion for the national immunization programme," which has expanded the existing six kinds of national immunization programmes and added hepatitis A vaccine, idemic encephalitis vaccines, encephalitis B vaccine, lepra vaccine into national immunization Planning for primary school children.

The expectation of Tiantan Biological in 2008: hepatitis B vaccine after the price rose in 2007, will expand its sales in 2008 and the market share will be recovery, Vero cellB and schizolysis influenza vaccine will continue to maintain growth steadily. The capacity of Plasma productions will remain same as 2007 in 2008, but the price of blood products will maintain high prices. The expectation of net profit will be up 15% in the first-quarter of 2008, the expectation of net profit in 2008 will be up 25%.

1. The brief of Tiantan
2.Analysis of the performance in 2007
2.1. The data of operating performance.
2.2. Analysis of the financial statements
2.3. Analysis of market
2.4.The impacting factors on the company performance
3.The operating performance of subsidiaries company
4. Main products
5. The national vaccine policy in 2008
6. Development Strategy of 2008


Charts
The profit targets, profit margins and cost rates of 2007
The Balance Sheet
The Major financial ratios
The profitability of the main indicators
The quarter business analysis
The profit report
Analysis of Quarter 2007 cumulative performance
The profitability indicators of 2007